Osiris Therapeutics Appoints General Manager of Market Access and Reimbursement

Columbia, Md.-based Osiris Therapeutics Inc., a stem cell technology company focused on wound care, orthopedic and sports medicine, has named Therésa K. Dixon, to general manager, market access and reimbursement, reporting to Lode Debrabandere, Ph.D., president and CEO.

“We are excited to add Therésa to our leadership team, with her proven track record and expertise in ensuring optimal market access and reimbursement,” said Debrabandere. “Therésa’s experience and understanding of the reimbursement landscape will undoubtedly help propel Grafix, Cartiform and OvationOS forward by improving patient access to our highly-differentiated products.”

Grafix and Ovation are for the treatment of acute and chronic wounds, and Cartiform is a viable cartilage mesh for cartilage repair. The latest addition to Osiris’ line of products is OvationOS, a viable bone matrix.

Dixon has 20 years of market access and reimbursement experience in the life science industry. She served as vice president of government affairs and health economics and a member of the senior leadership team at Advanced BioHealing Inc., (ANH), which was acquired by Shire in 2011. At ABH, she was responsible for the company’s government affairs, health policy and health economics initiatives for all regenerative medicine products, including Dermagraft’s industry-leading position in the reimbursement marketplace. Prior to ABH, she was the national director of health economics for Smith & Nephew plc, furthering its advanced medical devices in wound management, endoscopy and orthopedics. At Covance Health Economics & Outcomes Services (acquired by Corning Inc.), Dixon supported placement of a broad range of novel medical devices, pharmaceuticals and biologics into the U.S. healthcare payer system and marketplace. Dixon holds an MBA from the University of Maryland, an M.S. in Health Care Management from Marymount University, and a B.A. from the University of Missouri-Columbia.